Boundless Bio, Inc. (BOLD)
(Delayed Data from NSDQ)
$3.13 USD
-0.07 (-2.19%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $3.13 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Balance Sheet
Fiscal Year End for Boundless Bio, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 121 | 67 | -99,999 | -99,999 | -99,999 |
Receivables | 0 | 0 | NA | NA | NA |
Notes Receivable | 0 | 0 | NA | NA | NA |
Inventories | 0 | 0 | NA | NA | NA |
Other Current Assets | 3 | 1 | NA | NA | NA |
Total Current Assets | 124 | 68 | NA | NA | NA |
Net Property & Equipment | 3 | 3 | NA | NA | NA |
Investments & Advances | 0 | 0 | NA | NA | NA |
Other Non-Current Assets | 0 | 0 | NA | NA | NA |
Deferred Charges | 0 | 0 | NA | NA | NA |
Intangibles | 0 | 0 | NA | NA | NA |
Deposits & Other Assets | 1 | 1 | NA | NA | NA |
Total Assets | 130 | 77 | NA | NA | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | NA | NA | NA |
Accounts Payable | 4 | 3 | NA | NA | NA |
Current Portion Long-Term Debt | 0 | 0 | NA | NA | NA |
Current Portion Capital Leases | 2 | 2 | NA | NA | NA |
Accrued Expenses | 3 | 2 | NA | NA | NA |
Income Taxes Payable | 0 | 0 | NA | NA | NA |
Other Current Liabilities | 0 | 0 | NA | NA | NA |
Total Current Liabilities | 9 | 8 | NA | NA | NA |
Mortgages | 0 | 0 | NA | NA | NA |
Deferred Taxes/Income | 0 | 0 | NA | NA | NA |
Convertible Debt | 0 | 0 | NA | NA | NA |
Long-Term Debt | 0 | 0 | NA | NA | NA |
Non-Current Capital Leases | 0 | 3 | NA | NA | NA |
Other Non-Current Liabilities | 0 | 0 | NA | NA | NA |
Minority Interest (Liabilities) | 0 | 0 | NA | NA | NA |
Total Liabilities | 9 | 11 | NA | NA | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 248 | 148 | NA | NA | NA |
Common Stock (Par) | 0 | 0 | NA | NA | NA |
Capital Surplus | 9 | 5 | NA | NA | NA |
Retained Earnings | -136 | -87 | NA | NA | NA |
Other Equity | 0 | 0 | NA | NA | NA |
Treasury Stock | 0 | 0 | NA | NA | NA |
Total Shareholder's Equity | 121 | 66 | NA | NA | NA |
Total Liabilities & Shareholder's Equity | 130 | 77 | NA | NA | NA |
Total Common Equity | -127 | -82 | 0 | 0 | 0 |
Shares Outstanding | NA | NA | NA | NA | NA |
Book Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Fiscal Year End for Boundless Bio, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 179 | 105 | 121 | -99,999 | 0 |
Receivables | 0 | 0 | 0 | NA | 0 |
Notes Receivable | 0 | 0 | 0 | NA | 0 |
Inventories | 0 | 0 | 0 | NA | 0 |
Other Current Assets | 4 | 7 | 3 | NA | 0 |
Total Current Assets | 183 | 112 | 124 | NA | 0 |
Net Property & Equipment | 4 | 2 | 3 | NA | 0 |
Investments & Advances | 0 | 0 | 0 | NA | 0 |
Other Non-Current Assets | 0 | 0 | 0 | NA | 0 |
Deferred Charges | 0 | 0 | 0 | NA | 0 |
Intangibles | 0 | 0 | 0 | NA | 0 |
Deposits & Other Assets | 1 | 1 | 1 | NA | 0 |
Total Assets | 188 | 117 | 130 | NA | 0 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | NA | 0 |
Accounts Payable | 6 | 8 | 4 | NA | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | NA | 0 |
Current Portion Capital Leases | 1 | 2 | 2 | NA | 0 |
Accrued Expenses | 2 | 1 | 3 | NA | 0 |
Income Taxes Payable | 0 | 0 | 0 | NA | 0 |
Other Current Liabilities | 0 | 0 | 0 | NA | 0 |
Total Current Liabilities | 9 | 11 | 9 | NA | 0 |
Mortgages | 0 | 0 | 0 | NA | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | NA | 0 |
Convertible Debt | 0 | 0 | 0 | NA | 0 |
Long-Term Debt | 0 | 0 | 0 | NA | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | NA | 0 |
Other Non-Current Liabilities | 0 | 0 | NA | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | NA | 0 |
Total Liabilities | 9 | 11 | 9 | NA | 0 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 248 | 248 | NA | 0 |
Common Stock (Par) | 0 | 0 | 0 | NA | 0 |
Capital Surplus | 348 | 10 | 9 | NA | 0 |
Retained Earnings | -169 | -152 | -136 | NA | 0 |
Other Equity | 0 | 0 | 0 | NA | 0 |
Treasury Stock | 0 | 0 | 0 | NA | 0 |
Total Shareholder's Equity | 179 | 106 | 121 | NA | 0 |
Total Liabilities & Shareholder's Equity | 188 | 117 | 130 | NA | 0 |
Total Common Equity | 179 | -141 | -127 | 0 | 0 |
Shares Outstanding | 22.20 | 22.20 | NA | NA | NA |
Book Value Per Share | 8.07 | -6.36 | 0.00 | 0.00 | 0.00 |